Deanol and Loteprednol share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.250 means 25% of the combined target set is bound by both compounds. The IDF-weighted score of 0.239 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Deanol and Loteprednol have in common?
Deanol and Loteprednol share 2 molecular targets with a Jaccard similarity of 25%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Deanol and Loteprednol be combined?
Deanol and Loteprednol share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Deanol or Loteprednol?
Both Deanol and Loteprednol have substantial PubMed research. View their individual profiles for full evidence scores.